...
首页> 外文期刊>Retina >COMBINED VITRECTOMY WITH INTRAVITREAL DEXAMETHASONE IMPLANT FOR REFRACTORY MACULAR EDEMA SECONDARY TO DIABETIC RETINOPATHY, RETINAL VEIN OCCLUSION, AND NONINFECTIOUS POSTERIOR UVEITIS
【24h】

COMBINED VITRECTOMY WITH INTRAVITREAL DEXAMETHASONE IMPLANT FOR REFRACTORY MACULAR EDEMA SECONDARY TO DIABETIC RETINOPATHY, RETINAL VEIN OCCLUSION, AND NONINFECTIOUS POSTERIOR UVEITIS

机译:将玻璃体切除术与玻璃体外地塞米松植入植入糖尿病视网膜病变,视网膜静脉闭塞和非染色后葡萄炎

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: To compare the efficacy of intraoperative intravitreal dexamethasone implant for macular edema secondary to diabetic retinopathy (DME), retinal vein occlusion (RVO), and noninfectious posterior uveitis. Methods: A retrospective review of 62 patients (29 men and 33 women; mean age 51.19 +/- 14.41 years; 65 eyes) was performed. Best-corrected visual acuity (in logarithm of the minimal angle of resolution), central foveal thickness, intraocular pressure, and postoperative edema-free period were postoperatively assessed up to 1 year. The preoperative and postoperative numbers of other intravitreal injections needed were compared. Results: Best-corrected visual acuity gradually improved in the DME group (from 0.87 to 0.51) but failed to improve from Month 3 onward in the RVO and uveitis groups. Central foveal thickness decreased in all groups, especially in the DME group (from 550.93 to 338.10 mu m). Edema-free period was longest in the DME group (19.34 +/- 15.12 months), followed by the uveitis (12.91 +/- 7.85 months) and RVO (8.50 +/- 8.76 months) groups. Subjects in the uveitis group used more intraocular pressure-lowering agents (1.00 +/- 1.27) than those in the DME (0.13 +/- 0.49) and RVO (0.36 +/- 0.79) groups. Increased intraocular pressure events were most frequent in postoperative Week 1, especially in the uveitis group. Conclusion: Vitrectomy combined with intravitreal dexamethasone implant for DME, RVO, and noninfectious posterior uveitis had a favorable clinical outcome.
机译:目的:比较术中玻璃体内甲基塞纳酮植入物的疗效,用于糖尿病视网膜病变(DME),视网膜静脉闭塞(RVO)和非染色后葡萄膜炎。方法:对62名患者的回顾性审查(29名男性和33名女性;平均51.19 +/- 14.41岁; 65只眼睛)进行。最佳校正的视力(分辨率最小角度的对数),中央污水厚度,眼压和术后无水肿时期术后术后评估了1年。比较需要的术前和术后数量的其他玻璃体内注射。结果:DME组(0.87至0.51)逐渐改善最佳矫正视力,但未在RVO和葡萄炎群体中从3月3日开始改善。中央芯片厚度在所有组中减少,特别是在DME组(从550.93至338.10μm)中。 DME组(19.34 +/- 15.12个月)的水肿期最长,其次是葡萄炎(12.91 +/- 7.85个月)和RVO(8.50 +/- 8.76个月)组。 UVEITIS中的受试者比DME(0.13 +/- 0.49)和RVO(0.36 +/- 0.79)组的多种眼内降低剂(1.00 +/- 1.27)使用更多的眼内降低剂(1.00 +/- 1.27)。术后第1周,特别是在葡萄质炎组中,口服压力事件的增加最常见。结论:玻璃体切除与玻璃体内地塞米松植入DME,RVO和非染利后葡萄炎的植入物有良好的临床结果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号